Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients

Table 1 Comparison of time to symptom relief between the two groups (mean ± SD, d)

Group	n	Time to recovery of white blood cells	Time to recovery of body temperature	Time to disappearance of cough and expectoration	Time to disappearance of rales
Study	37	6.79 ± 2.09	4.15 ± 1.08	6.19 ± 1.56	6.68 ± 1.43
Control	37	8.89 ± 2.32	5.81 ± 1.33	8.77 ± 2.11	8.69 ± 2.12
t		4.091	5.894	5.981	4.781
P value		< 0.001	< 0.001	< 0.001	< 0.001

Table 2 Comparison of therapeutic effects between the two groups, n (%)

Group	n	Remarkably effective	Effective	Invalid	Total effectiveness
Study	37	23 (62.16)	12 (32.43)	2 (5.41)	35 (94.59)
Control	37	17 (45.95)	11 (29.73)	9 (24.32)	28 (75.68)
χ2					5.232
P value					0.022

Table 3 Comparison of laboratory indexes between the two groups before and 7 d after treatment (mean ± SD)

Group	n	PCT (ug/L)	CRP (mg/L)	WBC (× 109/L)	NE (%)
Before treatment
Study	37	12.89 ± 3.96	19.62 ± 6.44	20.61 ± 6.38	86.14 ± 7.21
Control	37	14.05 ± 4.11	18.79 ± 5.96	21.21 ± 5.59	84.39 ± 6.95
t		1.236	0.575	0.430	1.063
P value		0.220	0.567	0.668	0.291
After 7 d of treatment
Study	37	2.01 ± 0.56	3.11 ± 1.02	5.10 ± 1.83	56.35 ± 7.17
Control	37	3.29 ± 0.64	5.67 ± 1.23	8.13 ± 3.01	64.22 ± 8.08
t		9.155	9.745	5.232	4.432
P value		< 0.001	< 0.001	< 0.001	< 0.001

PCT: Procalcitonin; CRP: C-reactive protein; WBC: White blood cell count; NE: Neutrophil percentage.

Table 4 Comparison of the incidence of adverse reactions between the two groups, n (%)

Group	n	Pain at injection site	Skin itch	Vomiting and nausea	Gastrointestinal reaction	Total incidence rate
Study	37	1 (2.50)	0 (0.00)	2 (5.00)	0 (0.00)	3 (7.50)
Control	37	1 (2.50)	2 (5.00)	1 (2.50)	1 (2.50)	5 (12.50)
χ2						0.140
P value						0.708